Consistently, in AD patients, KLK6 was positively associated with markers of Tau pathology (CSF-pTau) and neuronal injury (CSF-tTau), and after correction for multiple testing, illustrating its similar potential as a marker for neurodegeneration. Here, MAPT is linked to Alzheimer disease.